CoChat
Sign Up
Cited by 196Gastrointestinal motility and disordersHealth Systems, Economic Evaluations, Quality of LifeInflammatory Bowel Disease

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

The validity and accuracy of the Work Productivity and Activity Impairment questionnaire—irritable bowel syndrome version (WPAI: IBS)

Reilly, M. C., Bracco, A., Ricci, J.‐F., Santoro, J., Stevens, T.·2004·Alimentary Pharmacology & Therapeutics
DOI 10.1111/j.1365-2036.2004.02091.x
Open this paper in CoChat — free account

Abstract

Summary: Background : Irritable bowel syndrome is a common chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and discomfort associated with alterations in bowel habit. Irritable bowel syndrome affects patients’ quality of life and increases productivity loss. Aim : To assess validity and accuracy of the Work Productivity and Activity Impairment questionnaire in irritable bowel syndrome as a tool for quantifying the effects of irritable bowel syndrome on productivity and daily activities. Methods : Validity and accuracy were evaluated in 135 irritable bowel syndrome patients relative to three measures of irritable bowel syndrome disease severity; a debriefing questionnaire; retrospective diary; Work Limitations Questionnaire, and an activity impairment measure (Dimensions of Daily Activities). Results : Symptom severity scores, diary scores, Work Limitations Questionnaire and Dimensions of Daily Activities were significant predictors of work productivity and activity impairment questionnaire in irritable bowel syndrome measures of work time missed, and work and activity productivity loss (P = 0.04 to < 0.0001). Impairment due to irritable bowel syndrome was estimated to be 2.9–4.3% for work time missed and 22–32% for impairment at work, the equivalent of 9.7 –14 h lost productivity per week. Activity impairment was 24–41%. Conclusions : Discriminative validity of the Work Productivity and Activity Impairment questionnaire in irritable bowel syndrome was established, making it the only validated tool for measuring the relative differences between disease severity groups and quantifying work productivity loss and activity impairment in irritable bowel syndrome patients.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02091.x

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Wahlqvist P, 2003, Resolution of upper gastrointestinal symptoms associated with chronic non‐steroidal anti‐inflammatory drug therapy has a positive impact on patient‐reported productivity, Gut, 52, A226
  2. Perrillo RP, 2000, Improved Work Productivity, Safety, and Quality of Life with Pegylated (40 kDa) Interferon ALFA‐2a (PEGASYS®) Therapy in the Treatment of Chronic Hepatitis C (Poster presentations)

Cited by

Sorted by citations

Items 101–196 of 196

Related

See all

Metadata

Authors
Reilly, M. C., Bracco, A., Ricci, J. ‐., Santoro, J., & Stevens, T.
Affiliations
Novartis (Switzerland) (CH)
Corresponding author
Reilly, M. C.
ORCID
Stevens, T.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-07-26
Volume
20
Issue
4
Pages
459-467
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1111/j.1365-2036.2004.02091.x
OpenAlex
W1994146596
Cited by
196
References
43
Citations by year
2026: 6 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 18 · 2020: 11 · 2019: 14 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 13 · 2013: 6 · 2012: 6
FWCI
3.67
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • Novartis Pharma
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
irritable bowel syndrome, Work Productivity and Activity Impairment, work productivity loss, activity impairment, discriminant validity, disease severity, Work Limitations Questionnaire, symptom severity, quality of life
MeSH terms
Absenteeism, Activities of Daily Living, Adult, Employment, Female, Health Status Indicators, Humans, Male, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review